NASDAQ:ALHC • US01625V1044
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALIGNMENT HEALTHCARE INC (ALHC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-01-16 | TD Cowen | Maintains | Buy -> Buy |
| 2026-01-14 | UBS | Maintains | Neutral -> Neutral |
| 2026-01-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-17 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-24 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-11-05 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-11-03 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-31 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-14 | Goldman Sachs | Initiate | Buy |
| 2025-08-25 | Keybanc | Upgrade | Sector Weight -> Overweight |
| 2025-07-31 | Barclays | Upgrade | Underweight -> Equal-Weight |
| 2025-05-02 | UBS | Maintains | Neutral -> Neutral |
| 2025-04-15 | Baird | Maintains | Outperform -> Outperform |
| 2025-04-08 | Stifel | Maintains | Buy -> Buy |
| 2025-03-06 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-03-04 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-04 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-28 | Stifel | Maintains | Buy -> Buy |
| 2025-02-28 | Barclays | Maintains | Underweight -> Underweight |
| 2025-02-24 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-01-14 | Stifel | Maintains | Buy -> Buy |
| 2025-01-02 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-12-03 | Stephens & Co. | Upgrade | Equal-Weight -> Overweight |
| 2024-10-31 | TD Cowen | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.824B 27.15% | 2.704B 48.25% | 3.949B 46.06% | 5.277B 33.64% | 6.598B 25.03% | 8.175B 23.90% | 10.646B 30.23% | 13.393B 25.80% | 11.841B -11.59% | |
| EBITDA YoY % growth | -106.149M 4.46% | -73.848M 30.43% | 45.868M 162.11% | 153.97M 235.68% | 219.18M 42.35% | 307.99M 40.52% | 453.39M 47.21% | 602.46M 32.88% | N/A | |
| EBIT YoY % growth | -127.817M 0.61% | -100.91M 21.05% | 15.386M 115.25% | 118.72M 671.61% | 177.5M 49.51% | 210.04M 18.33% | N/A | N/A | N/A | |
| Operating Margin | -7.01% | -3.73% | 0.39% | 2.25% | 2.69% | 2.57% | N/A | N/A | N/A | |
| EPS YoY % growth | -0.78 4.88% | -0.67 14.10% | -0.01 98.51% | 0.47 4,766.50% | 0.38 -19.13% | 0.73 94.59% | 1.45 97.22% | N/A | N/A |
All data in USD
| Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.13 83.16% | 0.05 147.86% | -0.05 -5.88% | 0.06 20.71% | 0.21 61.23% | 0.13 160.29% | -0.03 39.94% | 0.13 111.26% | 0.32 55.43% | 0.22 73.91% | 0.03 180.21% |
| Revenue Q2Q % growth | 1.345B 32.47% | 1.341B 34.95% | 1.351B 33.39% | 1.566B 26.78% | 1.688B 25.50% | 1.676B 24.98% | 1.678B 24.20% | 1.9B 21.33% | 2.096B 24.17% | 2.02B 20.53% | 2.03B 20.98% |
| EBITDA Q2Q % growth | 58.8M 57.17% | 43.104M 42.12% | 19.696M -2.49% | 48.132M 48.26% | 75.638M 28.64% | 60.757M 40.95% | 28.706M 45.75% | 61.567M 27.91% | 99.827M 31.98% | 90.301M 48.63% | 42.055M 46.50% |
| EBIT Q2Q % growth | 40.894M 79.77% | 25.428M 231.05% | 5.206M 150.62% | 18.255M 14.69% | 49.646M 21.40% | 32.108M 26.27% | -1.42M -127.28% | 52.255M 186.25% | 91.117M 83.53% | 80.631M 151.12% | 32.538M 2,391.26% |
All data in USD
19 analysts have analysed ALHC and the average price target is 25.84 USD. This implies a price increase of 30.18% is expected in the next year compared to the current price of 19.85.
The consensus EPS estimate for the next earnings of ALIGNMENT HEALTHCARE INC (ALHC) is 0.13 USD and the consensus revenue estimate is 1.34B USD.
The consensus rating for ALIGNMENT HEALTHCARE INC (ALHC) is 85.2632 / 100 . This indicates that analysts generally have a positive outlook on the stock.